Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 3, 2005, Pages 309-316

  Humbert, M ^a   Beasley, R ^b   Ayres, J ^c   Slavin, R ^d   Hebert J ^e   Bousquet, J ^f   Beeh, K M ^g   Ramos, S ^h   Canonica, G W ⁱ   Hedgecock, S ^j   Fox, H ^j   Blogg, M ^j   Surrey, K ^j  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^c Liberty Safe Work Research Centre   (United Kingdom)

^d SAINT LOUIS UNIVERSITY   (United States)

^e CRAAQ   (Canada)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

more..

Author keywords

Anti immunoglobulin E; Exacerbations; Global initiative for asthma 2002 step 4 therapy; Omalizumab; Severe persistent asthma

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OMALIZUMAB; PLACEBO; THEOPHYLLINE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE REACTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEVERE PERSISTENT ASTHMA; SINUSITIS; STATISTICAL ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, BETA-2; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20044362008     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00772.x     Document Type: Article

References (33)

1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162:2341-2351.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2002, 2003; accessed 26 October 2004). At: http://www.ginasthma.com.
3. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-665.
4. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157:1804-1809.
5. European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA). The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470-477.
6. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;2:CD000391.
7. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2:CD002985.
8. Evans DJ, Cullinan P, Geddes DM. Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;2:CD002987.
9. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B et al. Treatment of steroid-dependent bronchial asthma with cyclosporine. Eur Respir J 1995;8:1091-1099.
10. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723-729.
11. Serra-Batlles J, Plaza V, Morejon E, Comelia A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-1326.
12. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-642.
13. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184-190.
14. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261. Erratum in: Eur Respir J 2001;18:739-740.
15. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261. Erratum in: Eur Respir J 2001;18:739-740.
16. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638.
17. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-708.
18. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717.
19. Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-1094.
20. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-159.
21. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-78.
22. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233-240.
23. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.
24. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma. Chest 2004;125:1378-1386.
25. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Miller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
26. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-498.
27. Committee on Proprietary Medicinal Products. Notes for guidance on adjustment for baseline covariates. CPMP/ EWP/2863/99, 2003.
28. Weber EJ, Silverman RA, Callaham ML, Pollack CV, Woodruff PG, Clark S et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002;113:371-378.
29. Hartert TV, Speroff T, Togias A, Mitchel EF Jr, Snowden MS, Dittus RS et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467-473.
30. Taylor WR, Newacheck PW. Impact of childhood asthma on health. Pediatrics 1992;90:657-662.
31. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149 (3 Pt 1):604-610.
32. Burr ML, Davies BH, Hoare A, Jones A, Williamson IJ, Holgate SK et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54:985-989.
33. Jalaludin BB, Smith MA, Chey T, Orr NJ, Smith WT, Leeder SR. Risk factors for asthma deaths: a population-based, case-control study. Aust N Z J Public Health 1999;23:595-600.